Sales of Zecuity Migraine Skin Patches Halted

Share this content:
Sales of Zecuity Migraine Skin Patches Halted
Sales of Zecuity Migraine Skin Patches Halted

TUESDAY, June 14, 2016 (HealthDay News) -- Sales of the migraine treatment skin patch Zecuity (sumatriptan iontophoretic transdermal system) have been halted after patients reported suffering burns and scars where the patches were applied, Teva Pharmaceutical says.

The Israel-based company also said consumers with the disposable battery-powered patches should stop using them, the Associated Press reported.

The patch is designed to deliver a dose of medicine via a single-use, battery-powered patch that is wrapped around the upper arm or thigh. But some users have developed severe redness, skin discoloration, cracked skin, and pain where patches were applied, according to the U.S. Food and Drug Administration.

Teva said it is recalling the patches and working with the FDA to determine the cause of the skin reactions, the AP reported.

More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Pediatricians Should Provide Sexual Health Care Services

Pediatricians Should Provide Sexual Health Care Services

Office visits present opportunity to provide comprehensive education and health care services

Guidelines Updated for Infection Prevention in Pediatrics

Guidelines Updated for Infection Prevention in Pediatrics

Update focused on key principles of infection prevention, control relevant to ambulatory patients

2003 to 2014 Saw Drop in Urinary Arsenic in Public Water Users

2003 to 2014 Saw Drop in Urinary Arsenic ...

Reduction occurred after implementation of EPA's maximum contaminant level for arsenic

is free, fast, and customized just for you!

Already a member?

Sign In Now »